Certificados (CoA, COO, BSE/TSE y tabla de análisis)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculadoras de soluciones
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Reconstitution Calculator
Reseñas
Reseñas de cliente
Application Protocols
Not specified for this item; refer to CoA/Spec Sheet.
Biological Roles
Known biological function/target: Not specified for this item; refer to CoA/Spec Sheet.
Context for screening compounds (general guidance)
NRX‑1933 is listed within a small‑molecule/compound library category and is intended for discovery research. In this context, compounds serve as chemical probes or hit matter to interrogate biochemical pathways and phenotypes.
Without a disclosed structure or annotation, no endogenous role, pathway membership, or mechanism of action can be assigned. Any putative activity must be established experimentally and confirmed with orthogonal assays.
For cell‑based studies, document and control for potential confounders: autofluorescence, redox activity, metal chelation, detergent sensitivity, and nonspecific membrane disruption. Utilize counterscreens and target engagement assays (e.g., CETSA, NanoBRET) as appropriate.
If activity is observed, proceed with SAR expansion using close analogs, verify on‑target effects via genetic tools, and assess basic selectivity against common off‑targets relevant to the assay domain (kinases, GPCRs, ion channels, etc.)—all strictly for research use.
No biomedical, diagnostic, or therapeutic roles are claimed or implied for this product.
Buffer Applications
This product is not a buffer component per se, and no buffer‑related specifications are provided.
Practical notes for deploying small molecules in buffered assays (general guidance)
Vehicle effects: Match DMSO (or other vehicle) percentages across all wells/tubes to avoid buffer‑dependent artifacts.
pH and stability: If the compound is ionizable (unknown here), apparent potency and solubility can shift with buffer pH. Maintain pH within ±0.05 units and evaluate stability at assay temperature/time.
Protein binding: Inclusion of proteins (e.g., BSA) can sequester hydrophobic compounds; titrate protein content carefully and report free vs. total concentrations when possible.
Surfactants: Low levels of nonionic surfactants (e.g., 0.01–0.05% Tween‑20) may reduce aggregation/adsorption. Confirm compatibility with the assay readout.
Item-specific buffer guidance: Not specified for this item; refer to CoA/Spec Sheet if any special requirements (e.g., light protection, antioxidant) are noted.
Green Alternatives
This product is a small‑molecule screening compound rather than a bulk solvent or reagent; “green alternatives” therefore pertain mainly to solvent/vehicle choices during handling and assays.
Greener solvent considerations (general guidance)
Prefer DMSO over DMF/NMP when feasible due to lower toxicity and better biodegradability profile, while keeping final assay DMSO ≤0.1–1% v/v.
For aqueous delivery, consider
PEG400 or propylene glycol as minor co‑solvents (validate assay tolerance),
Cyclodextrin inclusion (e.g., HP‑β‑CD) to increase apparent solubility and reduce organic solvent needs,
Ethanol at low percentages where compatible with the biology and plastics.
Reduce plate waste by using acoustic dispensing or low‑dead‑volume tips, and by preparing miniaturized assay formats (e.g., 384‑/1536‑well) to cut solvent usage.
Tradeoffs
Greener co‑solvents may change assay baselines, protein stability, or plastic compatibility; rigorous controls are essential.
Cyclodextrins can alter free compound concentrations; determine binding constants or standardize inclusion ratios.
Note: Because NRX‑1933 structure is undisclosed here, do not assume aqueous compatibility or specific green solvent suitability without pilot tests. No item‑specific green attributes are specified; consult the CoA/Spec Sheet for any stability or compatibility notes.
Pharmaceutical Uses
No pharmacopeial status, excipient role, or manufacturing use is specified for this item; it is supplied strictly for research use only.
General considerations (not item-specific)
Discovery stage compounds may inform structure–activity relationships and preclinical hypothesis testing but are not manufactured under GMP, are not qualified as APIs or excipients, and are not suitable for clinical or diagnostic use.
Formulation experiments in research settings can explore solubilization approaches (DMSO stocks, co‑solvents, cyclodextrins, lipid vehicles) to support in vitro evaluations. Any in vivo or translational use would require separate sourcing under appropriate regulatory and quality frameworks—not covered here.
Item-specific statements
Pharmacopeia listings (USP/EP/JP): Not specified for this item; refer to CoA/Spec Sheet.
Residual solvent/elemental impurity controls: Not specified for this item; refer to CoA/Spec Sheet.
Stabilizers/antioxidants: Not specified for this item; refer to CoA/Spec Sheet.
Research Use Note: For research use only (as provided).
Physical Properties
Item-specific physicochemical data are not provided in the current listing. Do not assume values; consult the CoA/Spec Sheet supplied with your lot.
Typical property fields and current status (this item)
Appearance: Not specified for this item; refer to CoA/Spec Sheet.
Melting point: Not specified for this item; refer to CoA/Spec Sheet.
Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
Density: Not specified for this item; refer to CoA/Spec Sheet.
Refractive index: Not applicable/unknown for a solid; if liquid, Not specified for this item; refer to CoA/Spec Sheet.
Solubility: Not specified for this item; refer to CoA/Spec Sheet.
LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
pKa: Not specified for this item; refer to CoA/Spec Sheet.
UV–Vis λmax/UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.
General guidance (literature/practice, not item-specific)
For unknown small molecules used in screening, initial dissolution is commonly attempted in anhydrous DMSO (e.g., 10–50 mM stock), then diluted into assay buffer. Confirm solubility visually and by LC–UV or LC–MS.
If the compound is poorly soluble in DMSO, co-solvent blends (DMSO:H2O, DMSO:PEG400) or inclusion agents (e.g., 2‑hydroxypropyl‑β‑cyclodextrin) may be evaluated. Always verify assay compatibility.
Quality and Grades
Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.
How to interpret quality for screening compounds (general guidance)
Analytical characterization: Libraries are commonly qualified by LC–MS (identity and purity by UV/MS), and, where applicable, 1H NMR. Purity reporting often excludes residual solvent/water and salts; confirm the reporting basis on the CoA.
Purity thresholds: Screening collections typically target ≥90–95% purity by LC–UV at multiple wavelengths; however, this is not specified for NRX-1933. Verify the acceptance criteria for your application (e.g., biochemical vs. cell‑based assays).
Counter‑ion and form: Many small molecules may be provided as free base/acid or as a salt (HCl, TFA, etc.). Salt form and hydration/solvation significantly affect molecular weight and solubility; confirm on the CoA before preparing stocks.
Isomerism: If stereocenters or E/Z sites are present, ensure enantiomeric/diastereomeric composition is known. Chiral purity is not specified for this item.
Stabilizers: Not specified for this item; refer to CoA/Spec Sheet. If stabilizers or residual scavengers are present, consider assay interference testing (e.g., detergent screens, redox assay controls).
Documentation: For regulated or QC‑critical work, request full analytical package (chromatograms, spectra, methods) tied to your lot number.
Note: Research Use Only per listing; not intended for diagnostic or therapeutic use.
Reaction and Applications
Use-case focus: screening/deck compound for discovery research. No target, mechanism, or application specifics are provided for NRX‑1933; the points below are general best practices for small‑molecule evaluation.
Assay deployment: Prepare a concentrated DMSO stock (e.g., 10–50 mM; confirm actual concentration by weight/LC–UV). Perform serial dilutions to generate concentration–response curves (8–12 points, 1:3 or 1:2 series).
Controls: Include vehicle controls (matched DMSO), positive/negative assay controls, and counter‑screens to detect assay interference (redox cycling, fluorescence quenchers, metal chelation, detergent sensitivity).
Aggregation checks: Run nonionic detergent controls (e.g., 0.01% Triton X‑100) and light scattering/DLS when feasible. Consider detergent-sensitive PAINS filters carefully; confirm with orthogonal assays.
Stability: Evaluate stability in DMSO at freezer and room temperature, and in assay buffer at assay temperature/time. Use LC–MS to monitor decomposition or adduct formation.
Plate handling: Use low‑bind polypropylene plates/tubes. Minimize freeze–thaw cycles by aliquoting. Seal plates to limit DMSO evaporation; equilibrate to room temperature before opening to avoid condensation.
Orthogonal profiling: If a hit emerges, profile across biochemical and cell‑based assays, microsomal stability, and basic ADME surrogates to de‑risk artifacts. All such studies remain strictly research use.
No specific synthetic or named‑reaction applications are claimed for this item based on the provided data.
Reaction Conditions
No chemical transformation conditions are specified for NRX‑1933, and without structural information, prescriptive reaction chemistry is inappropriate.
General laboratory conditions relevant to handling/characterization (not item-specific)
Stock preparation: Dissolve at 10–50 mM in anhydrous DMSO, sonicate gently if needed, and verify concentration by weight or quantitative NMR/UV when possible.
Stability checks: Incubate aliquots at room temperature, 4°C, and assay temperature (e.g., 25–37°C) for representative durations (2–48 h). Analyze by LC–MS to confirm integrity and absence of reactive impurities.
Photostability: If the compound is chromophoric (unknown), protect from light during handling and assay setup; use amber vials/plates.
Adsorption: To reduce loss to plastics, use low‑bind polypropylene and pre‑wet tips with dosing solution. Evaluate recovery by LC–UV after simulated handling.
If you plan chemical reactions with NRX‑1933 (e.g., tagging/derivatization), first obtain the full structure and consult reaction‑specific literature for temperature, catalyst/base, and solvent choices. No yields, catalysts, or named‑reaction conditions are provided or implied for this item.
Safety and Handling
Safety information specific to this item is not provided in the listing.
GHS classification: Not specified for this item; refer to CoA/Spec Sheet and the product SDS for authoritative hazard statements and pictograms.
Signal word / H-statements / Pictograms: Not specified for this item; refer to SDS.
General laboratory precautions for small organic molecules (guidance only; defer to SDS)
PPE: Wear lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Avoid inhalation of dust/aerosols and prevent skin/eye contact. Handle powders in a fume hood or ventilated enclosure.
Handling: Minimize exposure of frozen materials to ambient humidity to prevent condensation. Allow vials shipped on dry ice to equilibrate in a desiccator before opening. For hygroscopic or air‑sensitive compounds, purge with inert gas after use.
Storage incompatibilities: Until specific functional groups are known, segregate from strong oxidizers, acids/bases, and reducing agents. Avoid light if the compound is potentially photosensitive; store in amber containers when in doubt.
First aid (overview): In case of contact, rinse affected area with water for 15 minutes and seek medical attention as needed. If inhaled, move to fresh air. If ingested, seek medical advice—do not induce vomiting unless directed.
Waste: Collect unused material and contaminated disposables as organic hazardous waste per institutional and local regulations.
Always review the lot-specific SDS before first use.
Solvent Selection
With no disclosed structure, solvent choice should follow a conservative solubility screening cascade suitable for small‑molecule screening stocks.
Recommended approach (general guidance)
Primary vehicle: DMSO is the default for discovery libraries due to broad solubilization and assay compatibility at ≤0.1–1% v/v in final wells.
Solubility screen: Test solubility at 10–50 mM in dry DMSO. If insoluble, evaluate NMP, DMF, or co‑solvent blends (e.g., DMSO:PEG400 1:1), ensuring biological compatibility upon dilution.
Aqueous delivery: For aqueous assays, consider pre‑dilution of the DMSO stock into buffer containing 0.01–0.05% nonionic surfactant (e.g., Tween‑20 or Pluronic F‑68) to mitigate aggregation/adsorption. Verify that surfactant does not affect the readout.
pH adjustment: If the compound has ionizable groups (unknown here), aqueous solubility may increase with pH adjustment; use minimal base/acid and confirm stability.
Comparison (general considerations)
DMSO vs DMF/NMP: DMSO is generally less noxious and more assay‑compatible; DMF/NMP can rescue difficult solubility but require tighter controls for cytotoxicity and leaching.
Aqueous co‑solvents: PEG400, propylene glycol, or cyclodextrins can improve delivery at low final organic percentages but may alter assay matrices—validate carefully.
Document the final vehicle composition in ELN and maintain constant solvent percentages across control and treated samples.
Storage and Reconstitution
Storage
Storage temperature (as provided): Store at −80°C.
Shipped on: Dry ice packs + cold packs (as provided). Inspect upon receipt; if thawing occurred, consult Technical Support before use.
General best practices: Keep tightly sealed in a desiccated, inert atmosphere if possible. Limit freeze–thaw cycles by preparing single‑use aliquots. Allow vials to reach room temperature in a desiccator before opening to minimize moisture condensation. Protect from light until photostability is known.
Reconstitution
Item-specific solvent and concentration: Not specified for this item; refer to CoA/Spec Sheet.
General guidance (not item-specific): Start with anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM), then dilute into assay buffer, maintaining consistent final vehicle percentage across samples. If solubility is limited, evaluate co‑solvents (PEG400, ethanol in small %), gentle warming (≤37°C), or sonication. Filter sterilize through 0.22 µm PTFE if sterility is required and compatible with solubility.
Documentation: Record exact solvent composition, concentration, and aliquot map in ELN. Label aliquots with lot number, concentration, and date.
Stability/retention
On‑bench working solutions in DMSO are commonly stable for hours; verify by LC–MS. Long‑term stability data for this item are not specified; conduct periodic QC on stored stocks.
Research Use Only, not for human or animal therapeutic or diagnostic use.
Structure and Identity
Concise identity summary for a small‑molecule library member intended for research screening. Item-specific identifiers are limited in the current listing.
SKU: N655954 (Aladdin Scientific)
Product Name: NRX-1933
CAS: 2763260-30-4
InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
SMILES: Not specified for this item; refer to CoA/Spec Sheet.
Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
Structural features
No structural diagram, ring system, or functional group annotation is provided in the current product data. If needed for cheminformatics ingestion, request the structure definition file (SDF/MOL) or SMILES via CoA/Spec Sheet.
Notes for users
Without a disclosed structure, treat NRX-1933 as an anonymized screening compound. For database registration or ELN compliance, use the CAS and SKU as primary keys until the full structure is provided.
If you plan physicochemical predictions (logP, pKa, PSA), obtain the canonical SMILES/InChI first; do not infer these properties from the product name alone.
Synthetic Utility
No functional group, reactivity, or building‑block use can be assigned to NRX‑1933 because the structure is not disclosed in the current product data. Consequently, it is not positioned here as a synthetic reagent but as a screening compound.
General perspective (not item-specific)
If structure becomes available and synthetic modification is desired (e.g., for SAR or biotin/fluorophore tagging), confirm the presence of vector sites amenable to diversification (halides, anilines, phenols, carboxylates, aldehydes, alkenes) and assess chemoselectivity.
For analytical confirmation of identity and purity during any derivatization workflow, use orthogonal methods: LC–MS with two stationary phases, 1H/13C NMR, and, if applicable, HRMS and 2D NMR.
Protecting‑group and late‑stage functionalization strategies (C–H activation, Minisci, photoredox) may enable rapid analog generation, but feasibility is entirely structure‑dependent.
Until the structural information is provided, treat NRX‑1933 as a finished compound for testing rather than a substrate or reagent in synthetic sequences.
Target Specificity
Not specified for this item; refer to CoA/Spec Sheet.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
